Imatinib for the treatment of patients with unresectable and/or metastatic gastrointestinal stromal tumours: systematic review and economic evaluation

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Declared competing interests of authors: D Peake has been paid by Novartis to give one lecture on GIST and was sponsored to attend the Third International Symposium on GIST. Other than this, members of the review team at the University of Birmingham have no any pecuniary relationship with sponsors, specific or non-specific. J Raftery is Director of the NCCHTA but he was not involved in the editorial process for this report. HTA Published July 2005This report should be referenced as follows: NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technolo...

Follow-up of gastro-intestinal stromal tumours (GIST) during treatment with imatinib mesylate by abdominal MRI

“…The annual incidence is at least 10-20 cases per million but might be higher [1][2][3]. GIST may be differed from leiomyomas, true leiomyosarcomas and schwannomas on histopathology by the immunohistochemical expression of CD 117 (c-kit proto-oncogen).…”

A pharmaco-economic analysis of second-line treatment with imatinib or sunitinib in patients with advanced gastrointestinal stromal tumours

“…The upper threshold recommended by NICE (d25 000 or about $51 300 USD) was used for the probabilistic-type sensitivity analysis since the oncology funds available by the IMSS have yet to be determined (Wilson et al, 2005). A hypothetical cohort of 1000 patients taking either sunitinib or seeking palliative care was constructed to demonstrate how the cost-effectiveness of therapy changes as the cost for intervention increases.…”

Cost analysis of the combined procedure of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)

“…[22] In comparison, the cost of one life-year saved is €75,000-146,000 for imatinib in unresectable gastro-intestinal stromal tumour (versus supportive care) and €103,000-120,000 for trastuzumab in metastatic breast cancer (versus standard chemotherapy). [23][24] Despite these important advancements, a peritoneal malignancy project in Italy does not receive an adequate financial support. Our current DRG classification does not include this procedure, resulting in a heavy economic deficit for the hospitals accepting the responsibility of treating these patients.…”